Rapidly Disintegrating Dosage Form Comprising Magnesium Carbonate Heavy
OwnerTorfi E. Kristjanssoninventor
Life of this patent
Estimating the term…
Abstract
A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is found to be an excellent dispersant under basic and neutral conditions, and gives the tablets a smooth mouth-feel.
Claims30
A dispersible dosage form for administrating a medicament, which disintegrates when in contact with water, comprising magnesium carbonate heavy as a dispersant and an active pharmaceutical substance.
A dispersible pharmaceutical dosage form comprising lamotrigine as an active ingredient, and further comprising:
- in the range of about 50-65 wt % magnesium carbonate heavy;
- in the range of about 10-30 wt % fine particle microcrystalline cellulose;
- in the range of about 3-10 wt % low-substituted hydroxypropyl cellulose;
- in the range of about 5-15 wt % crospovidone;
- in the range of about 4-20 wt % Avicel CE-15 mixture of microcrystalline cellulose and guar gum
A dispersible pharmaceutical dosage form comprising mirtazepine as an active ingredient, and further comprising:
- in the range of about 30-65 wt % magnesium carbonate heavy;
- in the range of about 10-30 wt % fine particle microcrystalline cellulose;
- in the range of about 3-10 wt % low-substituted hydroxypropyl cellulose;
- in the range of about 5-15 wt % crospovidone;
- in the range of about 4-20 wt % Avicel® CE-15 mixture of microcrystalline cellulose and guar gum.
A dispersible pharmaceutical dosage form comprising olanzapine as an active ingredient, and further comprising:
- in the range of about 20-60 wt % magnesium carbonate heavy;
- in the range of about 15-35 wt % fine particle microcrystalline cellulose;
- in the range of about 3-10 wt % low-substituted hydroxypropyl cellulose;
- in the range of about 5-15 wt % crospovidone;
- in the range of about 45-20 wt % Avicel® CE-15 mixture of microcrystalline cellulose and guar gum.
A dispersible pharmaceutical dosage form comprising risperidone as an active-ingredient, and further comprising:
- in the range of about 20-60 wt % magnesium carbonate heavy;
- in the range of about 15-35 wt % fine particle microcrystalline cellulose;
- in the range of about 3-10 wt % low-substituted hydroxypropyl cellulose;
- in the range of about 5-15 wt % crospovidone;
- in the range of about 4-20 wt % Avicel® CE-15 mixture of microcrystalline cellulose- and guar gum.
Dependencies are inferred from the claim text.